Delta Biosciences is a new-space chemistry company focused on developing next-generation pharmaceuticals and materials engineered for extreme and extraterrestrial environments. Building on a strong foundation in life sciences, the company integrates computational modeling, advanced synthesis techniques and high-throughput screening to design stable chemical solutions for applications in medicinal and space chemistry.

 
In 2026, Delta Biosciences will launch a landmark three-year drug stability mission aboard the International Space Station, conducted in collaboration with the European Space Agency. This mission will test the long-term stability and efficacy of radioprotective drug compounds and radiation-resistant excipients in LEO. By simulating prolonged exposure to cosmic radiation, the study aims to validate Delta’s hypothesis that tailored molecular formulations can extend the shelf-life of critical medical payloads during spaceflight.

 
The company is committed to pushing the boundaries of space chemistry and ensuring that human spaceflight is safer and more sustainable.